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This paper demonstrates how economic modelling can be used to derive estimates of the cost-effectiveness of prognostic markers in
the management of clinically localised and moderately graded prostate cancer. The model uses a Markov process and is populated
using published evidence and local data. The robustness of the results has been tested using sensitivity analysis. Three treatment
policies of ‘monitoring’ (observation), radical prostatectomy, or a selection-based management policy using DNA-ploidy as an
experimental marker, have been evaluated. Modelling indicates that a policy of managing these tumours utilising experimental
markers has an estimated cost per quality-adjusted life year (QALY) of d12 068. Sensitivity analysis shows the results to be relatively
sensitive to quality-of-life variables. If novel and experimental markers can achieve specificity in excess of 80%, then a policy of radical
surgery for those identified as being at high risk and conservative treatment for the remainder would be both better for patients and
cost-effective. The analysis suggests that a radical prostatectomy treatment policy for the moderately graded tumours (Gleason
grades 5 – 7) modelled in this paper may be inferior to a conservative approach in the absence of reliable prognostic markers, being
both more costly and yielding fewer QALYs.
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Prostate cancer is the commonest malignancy in men in the UK. In
1994, there were 20 000 new cases registered in England and Wales,
accounting for 15% of all cancers (Office for National Statistics,
2000). The widespread use of prostate-specific antigen (PSA)
testing is likely to have significantly increased this figure by 2001.
While the clinical course of each tumour is unpredictable, most
tumours are slow growing and many men with localised disease
live over 10 years after diagnosis (Chodak et al, 1994). Accurate
staging of prostate cancer is difficult to achieve and up to 45% of
tumours are regraded after surgical resection (Steinberg et al, 1997;
Ross et al, 1999). To date, the best prognostic indication is a
combination of the clinical stage, Gleason grade, and serum PSA at
diagnosis (Partin et al, 1997).
PSA testing in previously unscreened healthy younger men
(within or out with a screening programme) is increasingly
common. The increased incidence of affected younger men and the
downstaging effect of PSA testing have coincided with the
development of radical local treatments with curative intent on
locally confined cancer. More widespread PSA testing therefore is
likely to have significant resource implications both in terms of
testing and subsequent treatment. The development of one or
more prognostic markers that would more accurately predict
biological behaviour would enable the rationalisation of radical
treatment, and achievement of subsequent health and economic
benefits.
As with most human cancers, the era of molecular medicine has
brought to the fore potential markers of the biology of each
tumour. They have mostly failed to enter the clinical arena. This
paper utilises available information on the cell’s chromosomal
content (ploidy) as a template for modelling the role of prognostic
markers in prostate cancer. Ploidy has widely been suggested to
predict cancer behaviour (Schroder et al, 1994; Ross et al, 1999;
Bostwick et al, 2000; Montironi, 2001). The maintenance of
chromosomal balance (diploidy) is vital to a cell’s DNA stability
and loss is thought to herald a decline in differentiation with
imbalance of many oncogenes and tumour suppressor genes. In
addition, new automated image-based ploidy analysis machines
have been developed to allow rapid, reproducible, and reliable
ploidy analysis of tumour samples obtained by needle-core biopsy.
We have developed a model to analyse the economic and quality-
of-life effects of adding an experimental prognostic marker such as
ploidy to the traditional pathway of organ-confined prostate
cancer.
MATERIALS AND METHODS
A decision analytic Markov model was built using Microsoft
Excelt and populated using evidence from published literature
and local data sources. The Markovian structure of the model is
represented in Figure 1. A theoretical cohort of 1000, 60-year-old
men diagnosed with moderately differentiated (Gleason sum score
5 – 7) prostate cancer has been modelled, representing the majority
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of tumours seen in clinical practice (Han et al, 2001). The
aggressiveness of these moderately graded tumours is particularly
difficult to predict in the absence of additional reliable prognostic
markers.
The patient cohort is initially assigned to the state of having
being diagnosed with, and living with, early localised prostate
cancer. Patients either remain in this state (redefined as disease-
free for patients undergoing successful surgery), transfer to the
aggressive (metastatic) cancer state, or transfer to the end state
‘dead from other causes’. Three transitional states are also defined
for those patients who progress to the metastatic disease state.
These are: ‘living with metastatic disease’; ‘dead from prostate
cancer’; and ‘dead from other causes’. In each model state, patients
incur treatment costs and are assigned a quality-of-life utility.
Costs and benefits are accrued over the patient’s lifetime or until
40 years have elapsed, whichever occurs first. Total and
incremental costs and quality-adjusted life years (QALYs) for
three treatment policies are calculated. Future costs and benefits
are discounted for time preference at a rate of 6% per annum.
Based on the results for a nonscreened Swedish population
(Johansson et al, 1997), it is assumed that 22% of our modelled
cohort has cancers that are ‘true aggressive’ (i.e., they would
progress to metastases if untreated). Johansson’s data also suggest
that for this cohort of the population, the 15-year progression-free
survival rate is 6.2% and, that having progressed; the 15-year
survival rate is then 5.7%. These rates have been converted to
annual event probabilities in the model by assuming exponential
survival curves. The remaining 78% of the modelled cohort are
deemed to have ‘true localised’ cancers, and are assumed to have a
survival function determined by that of 60-year-old UK men
adjusted to exclude deaths from prostate cancer (HM Government
Actuarial Department, 2001).
Three policy options are modelled:
1. observation (also known as watchful waiting/monitoring) for
all;
2. surgical treatment for all (radical prostatectomy);
3. a selection-based policy, using DNA-ploidy as a prognostic
marker.
(1) Monitoring. Under the observation arm of the model, all
patients are assumed to have conservative treatment consisting of
PSA tests every 6 months for the first 2 years of treatment, and
every 12 months thereafter. These tests continue until the patient
dies or progresses to metastatic disease.
(2) Radical prostatectomy for all. The ‘radical prostatectomy for
all’ policy arm of the model assumes that the entire patient cohort
is given a prostatectomy following diagnosis of localised disease.
Based on published data (Dillioglugil et al, 1997), a 0.5%
perioperative death rate is assumed. A total of 25% of ‘true
aggressive’ cancers are assumed avoided following prostatectomy
(Kattan et al, 1997), such cancers then being modelled as if they
were ‘true localised’ following successful surgery.
(3) Prognostic marker-based selective radical intervention policy.
Patients with a diploid test are presumed to have less aggressive
disease, and are treated using ‘observation’ in the model. Patients
with a nondiploid test are assumed to have more aggressive
cancers, and are treated with prostatectomy. Having assumed
sensitivity and specificity values for the DNA-ploidy test, and also
what proportion of patients are ‘true aggressive’, Bayes theorem
was used to determine what proportion of patients would be
expected to have a diploid test result. Assuming a test sensitivity of
75% and a specificity of 85%, for example, and a ‘true aggressive’
cancer prevalence of 22%, positive and negative predictive values
are calculated to be 0.59 and 0.92, respectively (Table 1).
Treatment costs
An NHS costing perspective is taken so that direct patient costs
and indirect costs to the economy are ignored. Costs have been
inflated in the model to 2000/01 financial year prices using a
combination of hospital and community health services (HCSH)
and RPI inflators (Netten and Curtis, 2000; The Fairmount Group,
2001). All patients alive and free of metastases are assumed to have
two PSA tests for the first 2 years after diagnosis, and annually
thereafter. The blood test itself is assumed to cost d6 per test in
1995/96 prices (Chamberlain et al, 1997). It is assumed that
hospital consultants will want to review patients so that PSA
testing takes place during a hospital outpatient visit costed at d58
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Disease Progression
Disease Progression
Disease Progression
Dead from Prostate Cancer (CaP)
Dead from Prostate Cancer
Dead Other Causes
Dead Other Causes
Dead Other Causes
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Figure 1 Markov representation of early localised prostate.
Table 1 Relation between sensitivity, specificity, and predictive values*
Presumed
aggressive
Presumed
localised
True aggressive 0.165(a) 0.055 (b) 0.22 (a+b)
True localised 0.117 (c) 0.663 (d) 0.78 (c+d)
0.282 (a+c) 0.718 (b+d) 1.0 (a+b+c+d)
*The cell ‘a+b’ indicates prevalence of aggressive cancer (22%). Sensitivity and
specificity were set to be 0.75 (a/a+b) and 0.85 (d/c+d), respectively. Positive and
negative predictive values were then calculated to be 0.585 (a/a+c) and 0.923 (d/
b+d), respectively.
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per outpatient consultation (Netten and Curtis, 2000). The cost of
radical prostatectomy is estimated at d4938 using figures provided
by a local NHS Trust. This cost is similar to previously published
estimates (Chamberlain et al, 1997). The costs of DNA-ploidy
analysis have been estimated using confidential information
provided by an imaging company. The cost estimates that required
equipment life and usage estimates with discounting indicate that
staff rather than equipment costs dominate the costs of ploidy
analysis (d43 compared with d7), resulting in an estimated total
cost per test of d50. Patients progressing to metastatic disease are
assumed to have hormone treatment administered medically using
LH-RH analogues with an annual cost estimate of d1589 per
patient, based on BNF prices for Zoladex (Royal Pharmaceutical
Society of Great Britain, 2001). This treatment regimen is assumed
to continue until death.
Quality of life
Years spent alive are quality adjusted using utility values where
perfect health is represented by a utility score of one, and death is
represented by a value of zero. UK data suggest that men over the
age of 60 years have utility scores of 0.78 falling to 0.75 by the age
of 75 years (Kind et al, 1999). These utility scores have been used
to represent men assumed to have aggressive cancers removed by
prostatectomy with no complications following surgery. Patients
surviving radical prostatectomy are assigned an average utility
score of 0.70 to reflect the reduced quality-of-life experienced by a
proportion of surgery patients through peri- and postoperative
complications (notably persistent incontinence and/or impotence).
Meta-analyses of complication rates imply that 48% of radical
prostatectomy patients become impotent and remain impotent 18
months after surgery, and have an 18% risk of long-term
incontinence (Selley et al, 1997). Table 2 presents quality-of-life
utility values used in the model.
RESULTS
The central case assumptions described above were modelled. At
15 years, 19% of the untreated cohort is predicted to progress to
metastatic disease, and 14% to die of cancer. These results are
compatible with Johansson’s outcomes given that we have
modelled a younger population. Published sensitivity and speci-
ficity figures for Gleason grading in predicting aggressive cancers
are 73% and 84%, respectively (Veltri et al, 1996). The modelled
central scenario assumes sensitivity and specificity of 75% and
85%, respectively, for the ploidy marker. The resulting discounted
costs and QALYs for the three modelled treatment policies are
presented in Table 3. The table shows that observation is the least
cost policy (d1.6 m), whereas ‘surgery for all’ is considerably more
expensive at d6.4 m. The marker-based treatment selection policy
yields 107 more QALYs than the observation policy, resulting in an
incremental cost per QALY of d12068. ‘Prostatectomy for all’ is
dominated by the other two policies; that is, it is both more
expensive and yields fewer QALYs.
Sensitivity analysis
Given the lack of published sensitivity and specificity values for
ploidy in predicting aggressive prostate cancer, the sensitivity of
model outputs was tested by varying sensitivity and specificity
between the ranges 50% and 100%. The resulting incremental cost-
effectiveness ratios (ICERs) for the marker-based treatment policy
compared with observation are depicted graphically in Figure 2.
Using d30 000/QALY as a threshold range of acceptability for
healthcare interventions, modelling indicates that the marker-
based selection policy is cost-effective compared with observation
for most scenarios. For sensitivity and specificity of 50%, the
marker-based policy is dominated by observation (i.e. less effective
and more costly). Figure 3 illustrates the threshold combinations
of sensitivities and specificities that produce a cost per QALY of
d30 000. Combinations above and to the right of the isoquant
Table 2 Quality-of-life utility assumptions
Health state Utility
95% CI
(range) Source
Living with localised CaP 0.72 0.63 – 0.80 Cowen et al (1996)
UK male aged o75 years cured
of aggressive cancer by RP.
No complications
0.78 Kind et al (1999)
UK male aged 75+ years cured
of aggressive cancer by RP.
No complications
0.75 Kind et al (1999)
Metastatic CaP 0.42 0.33 – 0.51 Cowen et al (1996)
Impotence 0.69 0.61 – 0.77 Cowen et al (1996)
Incontinence 0.57 0.46 – 0.68 Cowen et al (1996)
Table 3 Modelled cost and QALY outcomesa
Cost QALYs Inc. cost/QALY
Observation d1 659 051 7095
Ploidy marker d2 948 177 7202 d12 068
RP for all d6 389 507 7068 Dominated
aCosts and QALYs discounted at 6%.
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Figure 2 Incremental cost-effectiveness ratio (costs per QALY for
marker treatment policy vs observation) by test sensitivity and specificity.
Specificity
0.5 0.6 0.7 0.8 0.9 1.0
0.5 Dominated 255 750 56 693 25 159 12 304 5323
0.6 471 520 80 259 36 513 19 673 10 755 5232
Sensitivity 0.7 109 040 49 198 27 630 16 514 9734 5168
0.8 63 464 36 248 22 633 14 461 9012 5119
0.9 45 613 29 145 19 429 13 019 8473 5081
1.0 36 090 24 658 17 200 11 951 8056 5051
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indicate costs per QALY below d30 000, and vice versa below and
to the left of the isoquant. The ICER is clearly more responsive to
changes in specificity than to sensitivity, and the marker test is
cost-effective for all combinations examined when the specificity is
78% or greater. For sensitivity and specificity values tested, the
number of QALYs from the marker-based treatment policy never
falls below the total achieved in the surgery policy central scenario.
Using a threshold ICER of d30 000/QALY, the sensitivity of the
ICERs for the marker-based selection policy with respect to
observation, and for the ‘surgery for all’ policy with respect to the
marker policy were tested using threshold analysis. The results of
the analysis are presented in Table 4. The results indicate that the
central scenario cost-effective result for the marker policy is pretty
robust for all variables except the utility values for quality-of-life
when living with the knowledge of having localised prostate
cancer, and impotence following prostatectomy. The former needs
only to vary from its central value of 0.72 outside the range
0.69 – 0.75 to render the cost-effectiveness of ploidy doubtful
compared to the alternative policies. Likewise, the central value for
impotence utility can only vary from 0.69 within the range 0.63 –
0.76. Table 4 indicates that many of the modelled input variables
can be changed to their extremes, and still the policy of ‘radical
prostatectomy for all’ does not become cost effective compared to
the selective marker-based policy. The shaded boxes highlight
those results where a feasible threshold value has been achieved,
but where radical prostatectomy is still dominated by the
observation treatment policy.
DISCUSSION
This paper has investigated the cost-effectiveness of a selective
treatment policy using a prognostic marker (DNA-ploidy) by
employing economic modelling techniques. Modelling by defini-
tion involves simplification of the real world. The lack of long-term
follow-up randomised controlled trial data makes modelling an
ideal analytical tool in this context (Fleming et al, 1993; Cantor
et al, 1995; Kattan et al, 1997; Yoshimura et al, 1998). The model
presented is concerned specifically with moderately graded
tumours in early stage localised prostate cancers, using DNA-
ploidy as a prognostic marker. The results must be viewed in this
context; however, the model could be used to model any defined
group of tumours and/or prognostic marker. Modelling has
indicated that a treatment selection policy based on DNA-ploidy
analysis would be cost-effective if the test can achieve specificity
levels at or above 80%.
The cost-effective result has been shown to be robust for a range
of sensitivity analyses. The ICER is most sensitive to the quality-of-
life assumptions for patients living with the knowledge that they
have untreated localised prostate cancer. The thresholds required
in order to change our cost-effective result lie within reported 95%
confidence intervals for this variable (Cowen et al, 1996; Kattan
et al, 1997). Our utility assumption for this variable lies in the
range 92% – 96% of full health for the age range modelled. Litwin
et al (2001) have reported that untreated early localised prostate
cancer may have lower quality-of-life scores, which would make
the marker and ‘prostatectomy for all’ policies more cost-effective
using this model. The result is also relatively sensitive both to the
frequency and quality-of-life assumptions associated with the
modelled post-prostatectomy complications of impotence and
incontinence. Our assumptions about the prevalence of impotence
and incontinence are consistent with Litwin’s data. Reduced levels
of complications following surgery, and, or higher utility scores for
these complications would again favour the marker-based selec-
tion policy and prostatectomy. Further research concerned with
guiding treatment policy for early localised prostate cancer should
ensure data collection on quality-of-life utility scores for key health
states.
Modelling has indicated that for moderately graded early
localised tumours, prostatectomy looks relatively expensive with
few QALY benefits compared to observation and marker selection-
based policies. Some authors have questioned the Johansson data
implying that the mortality and progression risks are low (Aus and
Hugosson, 1997; Walsh and Brooks, 1997). Higher mortality and
progression risks would shift the economic arguments more
towards the radical treatment options; however, our sensitivity
analysis indicates that these risks would have to increase
substantially before our results were invalidated for the central
scenario modelled.
Despite the current lack of evidence that screening for prostate
cancer prolongs survival and/or improves quality-of-life, PSA
screening may well increase in the UK, as men become more aware
of prostate cancer and demand PSA testing from their GPs
(Donovan et al, 2001). Screening implications have not been
modelled. Screening a wider population of men than occurs in the
UK currently is likely to mean a proportion of men being screened
who have no evidence of prostate cancer. This will have cost
implications. Also, the introduction of screening in the UK will
lead to the identification of earlier stage tumours than are
50%
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Figure 3 Threshold analysis showing cost per QALY of d30 000 for
ploidy marker selection policy compared with observation by test sensitivity
and specificity.
Table 4 Threshold sensitivity analyses
Variable
Base
case
assumption
Ploidy
marker vs
observation
ICERa=d30 000
Surgery
vs Ploidy
marker
ICERa=
d30 000b
Sensitivity 75% 34% NA
Specificity 85% 66% 12%
% True aggressive 22% 11% 67%
% Cured by surgery 25% 15% NA
15-year progression-free survival 6.2% 30% NA
15-year disease-specific survival 5.7% 96% NA
Utility (living with local CaP) 0.72 0.75 0.69
Utility (metastatic) 0.42 0.95 NA
Impotence (Utility) 0.69 0.63 0.76
Impotence (%) 48.4% 82% 10%
Incontinence (Utility) 0.57 0.40 0.76
Incontinence (%) 17.8% 32% 1%
P(peri-op death) 0.5% 43% NA
Cost of prostatectomy d4 938 d11,730 NA
Cost per ploidy test d50.26 d1 966 d7 485
Discount rate 6% 13% NA
aICER=incremental cost-effectiveness ratio.
bThe shaded boxes highlight those results where a feasible threshold value has been
achieved, but where radical prostatectomy is still dominated by the policy of
observation.
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currently being diagnosed. Both the aggressiveness of these
tumours and the life expectancies of the screened patients will
influence the modelled cost-effectiveness of the available treatment
options, and of screening itself. A range of survival and disease
progression assumptions could be analysed using this model to
help clinicians and patients alike in making difficult treatment
decisions in the management of prostate cancer as well as to assess
the cost-effectiveness of screening policies.
If novel and experimental markers can achieve specificity in
excess of 80% in predicting the aggressiveness of the tumours
modelled in this paper, then a policy of radical surgery for those
identified as being at high risk, and conservative treatment for the
remainder may be both better for patients and cost-effective. The
main caveats for the analysis and these conclusions surround
quality-of-life issues. There is a clear need to measure reliable
utility scores in future research to clarify the QALY benefits of
prognostic marker-based treatment policies and prostatectomy in
the management of prostate cancer. Models like the one presented
in this paper could be used to assess the cost-effectiveness of other
prostate cancer patient populations and alternative prognostic
markers.
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